UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm issued a lead-plaintiff solicitation for a securities fraud class action against Unicycive Therapeutics covering purchasers between December 29, 2025 and June 29, 2026. The suit alleges Unicycive failed to disclose it had not audited its third-party manufacturing vendor's FDA compliance, creating undisclosed risk that approval of oxylanthanum carbonate (OLC) would be delayed.
Key figures
- Class period end
- June 29, 2026
- Class period start
- December 29, 2025
- Lead plaintiff deadline
- November 2, 2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.